Background: The impact of FESS on OCS burden and HCRU in patients (pts) with CRSwNP is understudied.

Aims and objectives: To investigate OCS burden and HCRU in pts with CRSwNP with/without FESS, in US real-world practice.

Methods: US claims-based data (Optum; 2011?2021). FESS and non-FESS patients were propensity-score matched at baseline. OCS burden and HCRU were compared in the 1-year post-index date (intervention/follow-up periods: Day 0?44/45?365).

Results: Each group included 8,909 pts. During follow-up, OCS cumulative dose was approximately 18% lower in FESS vs non-FESS pts (mean difference in mg prednisone equivalents: ?40 mg [95% CI ?64, ?16] per pt); though in patients who filled an OCS prescription (34.6% vs 36.0%), OCS burden remained high (mean [SD] cumulative dose 521 [786] mg vs 612 [906] mg). Mean total healthcare costs were $28,832 and $2,537 per pt, respectively, during the intervention period, but similar during follow-up (Table 1). HCRU was similar during the follow-up period (Days 45?365), except that more FESS than non-FESS pts visited an otolaryngologist (57.5% vs 32.0%, p<0.01).

Conclusions: In real-world US practice, pts with CRSwNP undergoing FESS have a similar OCS burden to those not undergoing FESS, and with similar costs during follow-up.